In CLL, BMSCs produce HGF that promotes CLL cell survival via the activation of the Met/Stat3 pathways; this effect could be blocked with the SU11274 MET inhibitor [111]. Here, STAT3 is linked to B-cell chronic lymphocytic leukemia.